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Abstract
OBJECTIVES: We assessed the safety, effectiveness and haemodynamic performance of a new bovine stented aortic valve bioprosthesis
(AvalusTM).
METHODS: The PERIGON Pivotal Trial is a prospective, non-randomized, multicentre study. Subjects had symptomatic moderate or se-
vere aortic stenosis or chronic, severe aortic regurgitation. Death, valve-related adverse events (AEs), functional recovery and haemo-
dynamic performance were assessed at discharge, 3–6 months and 1 year. The primary analysis compared ‘late’ (>30 days post-implant)
linearized rates of valve-related thromboembolism, thrombosis, all and major haemorrhage, all and major paravalvular leak (PVL) and
endocarditis after implantation with objective performance criteria (OPC) for AEs, in accordance with EN ISO 5840:2009. We hypothesized
that the upper 95% confidence bounds of the true linearized AE rates would be >_ 2OPC; rejection of the null hypothesis would demon-
strate that these rates were below acceptable rates. The analysis was required to include at least 150 patients followed to 1 year and 400
valve-years. Kaplan–Meier survival analysis was also performed.
RESULTS: Total number of valve-years was 459.5 (n = 686). Linearized rates were <2OPC for death and valve-related thromboembolism,
valve thrombosis, all and major PVL, and endocarditis, but >_2OPC for all and major haemorrhage. Survival at 1 year (n = 270) was 96.4%.
Patients showed good functional recovery, and haemodynamic performance was within expected range.
CONCLUSIONS: This analysis demonstrated a good safety profile and clinical effectiveness of the Avalus valve except for bleeding rates.
The linearized rates of all and major haemorrhage may be related to long-term anticoagulation for non-valvular indications and the length
of follow-up of this cohort.
Trial registration: NCT02088554 (www.clinicaltrials.gov).
Keywords: Aortic valve replacement • Aortic stenosis • Bioprosthetic valves • Bovine pericardial valves • Avalus valve • Aortic valve
haemodynamics
INTRODUCTION
Surgical aortic valve replacement (AVR) is the second most fre-
quently performed cardiac operation, with nearly 50 000 procedures
performed in the USA in 2015 and probably an equal amount in
Europe [1]. In the population aged >65 years, approximately 1 in
every 1000 people will undergo AVR in the Western world [2].
Although transcatheter alternatives have been developed for high-
risk patients, most patients still are at low risk and are candidates for
a surgical procedure. At the end of the 20th century, about half of
the replacements were mechanical prostheses; nowadays, however,
>80% of replacements are biological prostheses [3]. With the ageing
of the population, this will undoubtedly increase over time.
†Presented at the 30th Annual Meeting of the European Association for
Cardio-Thoracic Surgery, Barcelona, Spain, 1–5 October 2016.
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The ideal valve substitute does not exist, and each prosthetic
valve has inherent limitations. Biocompatibility and the absence
of the need for anticoagulation are the most important advan-
tages of biological prostheses compared with mechanical valves,
while limited durability is one of their shortcomings. Other issues
related to valve prostheses are their implantability, pressure gra-
dients, regurgitation and thrombogenicity. These characteristics
drive the development of new prostheses with better perform-
ance. The AvalusTM valve (Medtronic, Minneapolis, MN, USA) is a
new pericardial bioprosthesis designed for easy implantability, a
low gradient across the valve and improved durability. In this re-
port, we present the first results from a multicentre trial investi-
gating the safety, effectiveness and haemodynamic performance
of this new prosthesis in a cohort of patients with aortic valve
disease and an indication for surgical AVR.
MATERIALS AND METHODS
Study design
The PERIcardial SurGical AOrtic Valve ReplacemeNt (PERIGON)
Pivotal Trial is a prospective, non-randomized, international,
multicentre trial to evaluate the safety and effectiveness of the
Avalus aortic valve bioprosthesis. The study was designed accord-
ing to the recommendations of the International Organization
for Standardization (ISO) standard for cardiac valve prostheses
(EN ISO 5840:2009) [4] and the US Food and Drug
Administration (FDA) heart valve guidance (2010) [5]. The trial is
being conducted at 36 sites in Europe, Canada and the USA.
This trial was designed and conducted in accordance with the
Declaration of Helsinki and good clinical practice guidelines. The
institutional review board of each centre approved the protocol,
and written informed consent was obtained from all patients. All
serious adverse events (AEs) and deaths were adjudicated by an
independent clinical events committee. All study echocardio-
grams were analysed by an independent core laboratory
(MedStar Health Research Institute, Washington, DC, USA). Safety
oversight was provided by an independent data and safety moni-
toring board. This trial is registered at www.clinicaltrials.gov,
NCT02088554.
Device and procedure
The Avalus aortic valve bioprosthesis is a bovine, stented, pericar-
dial tissue valve that has a supra-annular design and a lower pro-
file height than current bovine pericardial valves. Design details
are provided in Fig. 1. A disposable valve holder is attached to
the outflow of the valve to facilitate implantation. The valves sizes
available for this study were 17, 19, 21, 23, 25, 27 and 29.
The implant technique for the Avalus bioprosthesis is similar
to that for other stented aortic bioprosthetic valves. Surgeons
were allowed to use their preferred implant technique and car-
dioplegic and cardiopulmonary bypass strategies. Appropriate
postoperative anticoagulation therapy was left to the discretion
of the physician. Current practice is too disparate and the
guidelines inconclusive on the most appropriate postoperative
anticoagulation regimen to justify a prespecified protocol. Our
goal was to reflect the real world of surgical AVR as much as
possible.
Study population
Patients with moderate or severe aortic stenosis or aortic regurgi-
tation and a clinical indication for replacement of their native or
prosthetic aortic valve with a bioprosthesis were eligible.
Concomitant procedures were allowed but early in the study
were limited to left atrial appendage ligation, coronary artery by-
pass graft, patent foramen ovale closure, ascending aortic aneur-
ysm or dissection repair not requiring circulatory arrest or
resection of a subaortic membrane not requiring myectomy.
Patients found intraoperatively to require other procedures were
exited from the study and treated with a commercial valve.
Supplementary Material, Table S1, lists exclusion criteria. Patients
who met all inclusion criteria, no exclusion criteria, and provided
written informed consent were considered enrolled into the trial.
Baseline, perioperative and follow-up evaluations
Baseline evaluation included collection of demographic data,
medical history and use of relevant medications, particularly anti-
platelet and anticoagulant medications; physical examination;
Figure 1: Photograph and schematic of the Avalus bovine pericardial aortic bioprosthesis. AOA, alpha-amino oleic acid [6]; PEEK, polyether ether ketone.
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assessment of New York Heart Association (NYHA) functional sta-
tus and Society of Thoracic Surgeons (STS) score; 12-lead electro-
cardiography; haematology and chemistry tests, including serum
creatinine; and transthoracic echocardiography (TTE). Baseline
evaluations were required to be completed within 45 days before
the scheduled implant procedure except for TTE, which could be
completed within 90 days before implant.
Perioperative evaluation included collection of additional
required procedures or interventions, valve data, device failure or
malfunction, perioperative TTE, AEs or device deficiency and
medication use.
Patients who received the study valve were scheduled for
follow-up at hospital discharge (up to 30 days), 3 to 6 months
and 1 year. These visits included assessment of NYHA classifica-
tion, 12-lead electrocardiography, haematology and chemistry
data, TTE, medications and AEs or device deficiency. After the
1-year visit, follow-up will continue annually through 5 years.
Telephone follow-up calls will be made to assess vital status,
medications and AEs or device deficiency at 18 and 30 months.
Study end-points
Safety end-points were the incidence of valve-related death and
AEs over time, as defined by Akins et al. [7]. Valve-related AEs
included thromboembolism, thrombosis, all and major haemor-
rhage, all and major paravalvular leak (PVL) and endocarditis.
The primary analysis compared linearized valve-related AE rates
after valve implantation with the objective performance criteria
(OPC) defined by the ISO and FDA for commercially available
tissue valves [4, 5] (Supplementary Material, Table S2). The ISO
and FDA guidance requires that new or modified bioprostheses
perform as well as or better than the OPC for valve-related AEs.
Linearized rates of late AEs were determined because the risk of
an AE is assumed to remain constant over time after valve im-
plantation. We hypothesized that the upper 95% confidence
bounds of the true linearized valve-related AE rates for the
study valve would be >_2OPC. Secondary safety end-points
included the incidence of reinterventions and explants over
time.
Effectiveness end-points were NYHA functional classification
and haemodynamic performance, including effective orifice area
(EOA) indexed EOA (EOAi), and mean and peak aortic pressure
gradients. Prosthesis–patient mismatch (PPM) was defined as fol-
lows: none/mild, EOAi > 0.85 cm2/m2; moderate, EOAi >0.65–
<_0.85 cm2/m2; and severe, EOAi <_ 0.65 cm2/m2 [8].
Statistical analysis
The EN ISO 5840:2009 standards require that analyses be based
on (i) a minimum of 150 patients followed up for 1 year and (ii)
at least 400 valve-years of follow-up [4]. These standards also
specify that all implants are to be included in the analysis.
These requirements are based on the method of Grunkemeier
et al. [9].
Descriptive statistics are used to report clinical characteristics
and echocardiographic data. For categorical data, the number
and percentage of patients in the category are presented. For
continuous data, the mean ± standard deviation are presented.
Early AE rates (those occurring <_30 days post-implant) were cal-
culated as the number of early events/total number of subjects,
expressed as a percentage. Linearized rates of late AEs were
calculated as the total number of late events (those occurring
>30 days post-implant) divided by the total follow-up time (the
sum of accumulated late postoperative valve-years), expressed as
a percentage. For AEs with OPC available, the linearized rates
and their associated 1-sided upper 95% confidence bounds were
compared with 2 the OPC rate. We hypothesized that the
upper 95% confidence bounds of the true linearized valve-
related AE rates for the study valve would be >_2 times greater
than the OPC. If the upper 95% confidence limit for a complica-
tion rate is <2 the OPC rate, the null hypothesis can be rejected
at a 1-sided significance level of 0.05 [5, 9]. Kaplan–Meier survival
analyses were also performed.
RESULTS
From May 2014 through January 2016, 753 subjects were enrolled
into the PERIGON Pivotal Trial. Among the enrolled patients, 1
died and 66 withdrew before implantation (Supplementary
Material, Table S3, lists reasons for withdrawal). This analysis in-
cludes 459.5 valve-years of follow-up with 686 subjects having
received an implant and 270 subjects having completed 1 year of
follow-up, thereby meeting the requirements of the ISO guidance.
The total number of late (>30 days) valve-years was 405.3 (n = 683).
Figure 2 shows patient disposition from enrollment through 1
year. One hundred twenty patients were enrolled before the inclu-
sion and exclusion criteria were updated.
Figure 2: Patient disposition from screening through 1-year follow-up
evaluation.
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Table 1 presents baseline patient characteristics. The study
population consisted of typical patients referred for AVR with
common comorbid conditions. STS criteria [10] indicated 627
(91.4%) patients were at low risk of mortality (predicted risk of
mortality [STS PROM] <4%), 55 (8.0%) were at intermediate risk
(STS PROM 4–8%) and 4 (0.6%) were at high risk (STS PROM
>8%). Nearly 80% had received no previous coronary interven-
tion, and only 2 (0.3%) had undergone prior AVR.
Procedural details
Table 2 provides procedural information, including indications for
AVR and surgical approaches used. Among the 686 implanted
valves, 210 (30.6%) were placed with simple interrupted sutures, 369
(53.8%) with pledgeted mattress sutures, 39 (5.7%) with a continuous
running technique, 42 (6.1%) with everted mattress sutures, 316
(46.1%) with non-everted mattress sutures, 2 (0.3%) with a figure of
eight suture, 72 (10.5%) with Cor-Knot fasteners and 17 (2.5%) with
another technique. The valve was placed in an intra-annular pos-
ition in 111 patients (16.2%) and the supra-annular position in 555
(80.9%). Mean total aortic cross-clamp time was 77.6 ± 30.8 min; for
isolated AVR (n= 338), it was 65.4 ± 23.1 min; and for combined pro-
cedures (n= 348), 89.5 ± 32.8 min. Supplementary Material, Fig. S1,
shows valve size distribution.
Clinical events
Figure 3 compares the late linearized rates and upper 95% confi-
dence limits for valve-related AEs to OPC. As shown, the upper
95% confidence limits of the late linearized AE rates were below
2 OPC for all events except all and major haemorrhage. Details
about the bleeding events are provided in the Supplementary
Material.
There were 21 deaths (7 up to 30 days and 14 >30 days post-
implant); 2 were valve related and 7 were cardiac deaths. The
Kaplan–Meier estimates of freedom from all-cause, cardiac and
valve-related mortality at 1 year were 96.4% (95% CI 94.1–97.8),
98.9% (95% CI 97.4–99.5) and 99.6% (95% CI 97.4–99.9), respect-
ively. No valve thrombosis, haemolysis or structural valve deteri-
oration was observed throughout the study period. The early
mortality rate was 1.0% (n = 7) overall, 0.7% (n = 5) among low-
risk patients, 0.3% (n = 2) among intermediate-risk patients, and
0.0% (n = 0) among high-risk patients. Supplementary Material,
Table S4, shows additional early safety end-points. As shown, the
Table 1: Baseline patient characteristicsa,b
Characteristic Patients (n = 686)
Age (years) 70.5 ± 9.2
Male 506 (73.8%)
Body surface area (m2) 2.0 ± 0.2
NYHA Class
I 76 (11.1%)
II 324 (47.2%)
III 273 (39.8%)
IV 13 (1.9%)
STS mortality risk (%) 2.1 ± 1.4
STS morbidity/mortality risk (%) 15.0 ± 6.1
Comorbid conditions
Coronary artery disease 282 (41.1%)
Congestive heart failure 150 (21.9%)
Hypertension 525 (76.5%)
Angina 276 (40.2%)
Dyslipidaemia 400 (58.3%)
Smoking 315 (45.9%)
Current smoking 51 (7.4%)
Left ventricular hypertrophy 273 (39.8%)
Diabetes 178 (25.9%)
Endocarditis 2 (0.3%)
Rhythm on ECG
Sinus rhythm 548 (80.1%)
Pacing 14 (2.0%)
Atrial fibrillation 32 (4.7%)
Other 90 (13.2%)
Previous coronary interventions
Coronary artery bypass graft 20 (2.9%)
Percutaneous coronary intervention 90 (13.1%)
Implanted cardiac device 20 (2.9%)
Percutaneous valvuloplasty 1 (0.1%)
Previous aortic valve implant 6 (0.9%)
Previous open-heart surgeries
1 27 (3.9%)
2+ 1 (0.1%)
aValues are mean ± SD or n (%).
bSupplementary Material, Table S5, contains additional baseline
characteristics.
Table 2: Procedural details
Procedural information Subjects (n = 686)
Primary indication for AVR
Aortic stenosis 587 (85.6%)
Aortic regurgitation 37 (5.4%)
Mixed 59 (8.6%)
Failed prosthesis 3 (0.4%)
Surgical approach
Median sternotomy 540 (78.7%)
Hemisternotomy 96 (14.0%)
Right thoracotomy 38 (5.5%)
Other 12 (1.7%)
Combined procedures
None 338 (49.3%)
Coronary artery bypass graft 225 (32.8%)
Left atrial appendage closure 49 (7.1%)
Patent foramen ovale closure 4 (0.6%)
Ascending aortic aneurysm not requiring
circulatory arrest
41 (6.0%)
Myectomy 21 (3.1%)
Ascending aorta replacement 20 (2.9%)
Annular enlargement 3/125 (2.4%)
Aortotomy enlargement 17/126 (13.5%)
Resection of subaortic membrane not
requiring myectomy
12 (1.7%)
Maze procedure 12 (1.7%)
Dissection repair not requiring
circulatory arrest
1 (0.1%)
Aortic arch replacement 2 (0.3%)
Mitral valve replacement (unplanned) 1 (0.1%)
Root replacement 1 (0.1%)
Other 22 (3.2%)
Total bypass time (min) 102.6 ± 39.3
Isolated AVR 88.8 ± 30.3
AVR + combined procedures 116.1 ± 42.2
Values are mean ± SD or n (%).
428 R.J.M. Klautz et al. / European Journal of Cardio-Thoracic Surgery
Downloaded from https://academic.oup.com/ejcts/article-abstract/52/3/425/3798543
by guest
on 29 June 2018
rates of endocarditis, reintervention and explant were all very
low. Table 3 provides medication use at each office follow-up
visit. The Supplementary Material contains additional informa-
tion about anticoagulation.
Effectiveness
Figure 4 illustrates NYHA functional classification at baseline, 3–6
months and 1 year. Nearly three-fourths of patients improved 1
or 2 classes from baseline to 1 year, whereas 1.5% worsened by 1
class over the same period.
Haemodynamic performance
Figure 5 illustrates the mean aortic gradient and EOA from base-
line through the 1-year evaluation, showing improvement in
these parameters after AVR. Peak aortic gradient was 67.9 ± 25.3
at baseline, 24.2 ± 8.6 at discharge/30 days, 22.3 ± 7.7 at 3–6
months and 23.3 ± 7.7 at 1 year. Mean EOAi for all valves was
0.44 ± 0.25 at baseline, 0.80 ± 0.19 at discharge/30 days,
0.80 ± 0.18 at 3–6 months and 0.76 ± 0.16 at 1 year. The propor-
tion of subjects with no, moderate and severe PPM at 1 year was
24.4%, 50.0% and 25.6%, respectively.
Regurgitation
PVL was classified as none or trace in >94% of patients at dis-
charge/30 days, 3–6 months and 1 year. Mild PVL was observed
in 1.8%, 3.0% and 1.2% of patients at the same time points, re-
spectively. Moderate PVL occurred in 0.5% of patients at 3–6
months. There were no cases of severe PVL.
Transvalvular regurgitation (TVR) was classified as none or
trace in >_93% of patients at the 3 evaluations. Mild TVR was
observed in 3.3% of patients at discharge/30 days, 4.5% at 3–6
months and 4.7% at 1 year. One patient (0.2%) had moderate
TVR at the 3- to 6-month visit, and none was found to have se-
vere TVR.
DISCUSSION
In this first analysis of the PERIGON Pivotal Trial, we found low
rates of early and late mortality and valve-related AEs and
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Figure 3: Valve-related late adverse events (>30 days to 1 year) compared with
2 objective performance criteria (OPC). Error bars indicate 95% upper bound
of late linearized rate for each event.
Table 3: Antiplatelet and anticoagulant use at baseline and follow-up visits
Visit Antiplatelet Anticoagulant Antiplatelet + anticoagulant No medication
Baseline (n = 686) 386 (56.3%) 43 (6.3%) 30 (4.4%) 227 (33.1%)
Discharge (n = 683) 373 (54.6%) 71 (10.4%) 230 (33.7%) 9 (1.3%)
3-6 months (n = 612) 411 (67.2%) 54 (8.8%) 97 (15.8%) 50 (8.2%)
1 year (n = 270) 195 (72.2%) 25 (9.3%) 26 (9.6%) 24 (8.9%)
Figure 4: New York Heart Association (NYHA) classification from baseline
through 1-year follow-up evaluation.
Figure 5: Haemodynamic performance from baseline through 1-year follow-
up evaluation.
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improvement in NYHA functional status and haemodynamic
performance.
The mortality rates in this study compare favourably with
those reported for other bioprostheses. We observed an early
mortality rate of 1.0%, compared with 30-day mortality rates of
1.8% reported for the Trifecta valve [11] and 2.0% and 0% re-
ported for the Magna Ease and Trifecta valves, respectively [12].
Our rate of freedom from all-cause mortality at 1 year (96.4%)
was similar to the rates reported for the Trifecta (95.8% and
96.0%) and Magna Ease (90.6%) valves [11, 12]. In the Nordic
Aortic Valve Intervention (NORDIC) Trial, an all-comers random-
ized study comparing surgical and transcatheter AVR, the 1-year
all-cause mortality rate in the surgical AVR group was 7.5%
(Kaplan–Meier estimate) [13].
Both early event rates and late linearized rates for other valve-
related safety outcomes compared favourably with results re-
ported for the Trifecta valve [11]. In both studies, there were no
early or late cases of valve thrombosis, major PVL, structural valve
deterioration or haemolysis. Late linearized rates were similar for
all other valve-related AEs, including thromboembolism (Avalus
and Trifecta, respectively: 2.2% and 1.9% per valve-year), PVL
(0.5% and 0% per valve-year), endocarditis (1.0% and 1.1% per
valve-year), non-structural valve dysfunction (0.5 and 0.1% per
valve-year), reintervention (0.5% and 0.6% per valve-year) and
explant (0.5% and 0.6% per valve-year).
The primary results for bleeding were somewhat unexpected,
though also reported by others on biological valves [11]. There
were 15 late all-haemorrhage events (n = 13), 11 of which were
major (n = 9). These events yielded late linearized rates of 3.7%
per valve-year and 2.7% per valve-year, respectively; with upper
bounds of 5.6% and 4.3%, both exceeded the 2 OPC rates
of 2.8% and 1.8% per valve-year. The current analysis includes
1-year data for only 270 of 686 (39%) implanted patients, so it is
likely the linearized rates calculated for haemorrhage are inflated
owing to the proportion of patients still receiving prophylactic
anticoagulant administration following implantation. As ex-
plained in Methods, linearization assumes a relatively constant
rate of events over time. This is clearly not true for bleeding, as
these events are much more frequent in the early months of
follow-up (3–6 months postoperatively) than in the later months
after implant. Linearization, or extrapolation from these early
months to 1 year, yields a rate that is likely higher than would
be the case if the entire follow-up of 1 year would have been
captured. In addition, two-thirds of the patients were taking an
antiplatelet or anticoagulant agent, or both, at baseline for non-
valvular indications. Eleven of the 15 all-haemorrhage events
occurred in patients taking warfarin (CoumadinV
R
) or other anti-
coagulants, such as dabigatran (PradaxaV
R
), clopidogrel (PlavixV
R
)
or heparin. In patients taking chronic anticoagulation for comor-
bid conditions such as atrial fibrillation, the presence of a bio-
prosthesis does not directly affect the risk of an anticoagulant-
related haemorrhage event. Rather, the risk of anticoagulant-
related bleeding is more likely attributable to the management of
the anticoagulation regimen for non-valvular indications. In fact,
only 1 bleeding event was directly related to anticoagulation
taken to prevent early thrombosis after implantation (see
Supplementary Material). As with other tissue bioprostheses, the
instructions for use of the Avalus valve recommend anticoagula-
tion during the initial healing stages following implant. Thus, the
risk of anticoagulant-related haemorrhage is increased during
this time. However, the use of anticoagulation in this study
decreased over time (Table 3), but 11 of the 15 late haemorrhage
events occurred during the early postoperative months, between
31 days and 6 months. These findings, along with the wide vari-
ability of anticoagulation usage, suggest that bleeding events
might not be a very useful performance criterion for bioprosthe-
ses considering the current OPC definition of a ‘late’ event (>30
days post-implant). However, because this is an ISO requirement,
it was kept in the analysis.
NYHA functional classification was improved in almost all pa-
tients receiving the Avalus valve with only 4.4% of patients in
Class III and none in Class IV at 1 year, comparable to other com-
mercially available valves [11] and proving the effectiveness in
treating aortic valve disease. The mean pressure gradient for all
valve sizes in our cohort was 13.6 ± 4.8 mmHg at discharge/30
days, 12.2 ± 4.2 mmHg at 3–6 months and 12.6 ± 4.3 mmHg at 1
year. In recent studies of other valves, mean gradients ranged
from 9.1 ± 3.9 to 14.0 ± 5.0 mmHg at discharge, 8.9 ± 3.9 to
11.4 ± 3.1 at 6 months and 9.4 ± 4.3 to 12.9 ± 3.8 at 1 year [12, 14].
EOAs in this cohort were 1.6 ± 0.4 cm2 at discharge/30 days,
1.6 ± 0.4 cm2 at 3–6 months and 1.5 ± 0.4 cm2 at 1 year, which
compare favourably with EOA values ranging from 1.5 ± 0.3 to
1.8 ± 0.4 cm2 at discharge, 1.6 ± 0.5 to 2.1 ± 0.5 cm2 at 6 months,
and 1.4 ± 2.4 cm2 and 1.7 ± 0.4 at 1 year for other valves [11, 12,
14]. These differences are clinically insignificant, and all these
contemporary pericardial valves seem to perform well. The pro-
portion of subjects with moderate or severe PPM in our study
was 50.0% and 24.4%, respectively, at 1 year. Severe PPM has
been reported in 20.7% to 33.9% of patients undergoing surgical
AVR in clinical trials comparing surgical and transcatheter AVR
[15–17]. The meaning of severe PPM has been questioned [18]
and should be interpreted with caution.
Limitations
Due to the design of the study, the 1-year results could be re-
ported on only 270 patients. This analysis was designed to meet
the requirements of EN ISO 5840:2009 [4], which required at least
150 patients followed to 1 year and at least 400 valve-years.
However, because the PERIGON Pivotal Trial was powered to
meet the requirement of the US FDA [5], a minimum of 800
valve-years is needed to accurately detect the smallest acceptable
haemorrhage event rate (1.2%) with a power of 0.80; even more
valve-years will be required for major haemorrhage. In addition,
the majority of patients in this cohort had not completed their
1-year visit and were in the early postoperative period. It is likely
that many of those patients were still receiving anticoagulation
and thus had a higher risk of bleeding events. Furthermore, the
exclusion criteria became more restrictive after the first 120 pa-
tients were enrolled, as did the allowable combined procedures,
which may have influenced early bleeding events.
Another limitation is that we did not include a control arm.
A true control group is difficult to define as all commercial valves
have their own benefits and limitations; there is no ‘gold stand-
ard’ for AVR studies. We therefore elected to compare this valve
to OPC as many new valves have been tested against the same
standards.
This article describes safety and efficacy of a new bioprosthesis.
The most important information for these types of prosthesis,
however, is durability. Although several design features have
been incorporated in this new valve to increase its durability,
only longer term follow-up studies can demonstrate this
promise.
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CONCLUSIONS
This analysis demonstrated a good safety profile and haemo-
dynamic performance of the Avalus valve except for bleeding
rates. The upper 95% confidence bounds of the late linearized
rates were <2 OPC for death and valve-related thromboembol-
ism, thrombosis, all and major PVL and endocarditis. The late
linearized rates of all and major haemorrhage were >2 OPC but
appear to be related to long-term anticoagulation for non-valvu-
lar indications and the length of follow-up in this cohort.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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